Medical Radiology and Radiation Safety. 2026. Vol. 71. № 6
DOI:10.33266/1024-6177-2026-71-6-19-24
E.A. Mysina1, N.A. Pivovarov1, B.A. Bokl1, A.E. Shemyakov1, 2, A.L. Popov1
INFLUENCE OF DIFFERENT TYPE OF RADIATION ON THE CELL SURVIVAL FROM 3D TUMOUR SPHEROIDS FORMED FROM B16/F10 MELANOMA CELLS
1 Institute of Theoretical and Experimental Biophysics, Pushchino, Russia
2 P.N. Lebedev Physical Institute, Protvino, Russia
Contact person: A.L. Popov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Relevance: Proton therapy is considered one of the most promising methods for treating difficult‑to‑localize tumors, although it still has some drawbacks, which requires the development of new approaches to improve its effectiveness. One of the most promising approaches is the use of radiosensitizers capable of enhancing the radiation‑induced effects of a proton beam. At the same time, the use of 2D tumor cell models for screening potential radiosensitizers is insufficient for effectively translating the obtained experimental data to the in vivo level. 3D cell spheroids are a convenient and relevant model for studying new approaches to the therapy of solid tumors, as they allow simulating the microenvironment of tumor cells and modeling in vivo conditions, including the presence of the intercellular matrix and the formation of a specific zonality.
The main goal of this study was to create an experimental model of a tumor spheroid based on tumor cells of the B16/F10 line, which would be irradiated with X‑rays and a proton beam, for subsequent use in screening potential nanoradiosensitizers.
Purpose: To investigate the effect of X‑ray radiation and proton irradiation at the Bragg peak over a wide dose range (0–12 Gy) on the viability of 3D cellular tumor spheroids formed from B16/F10 mouse melanoma cells.
Material and methods: The biological effect of the radiation was assessed in vitro using a culture of B16/F10 cells (mouse melanoma). The hanging drop method was used to form cellular spheroids. The cell spheroids were irradiated with a proton beam at the Bragg peak using the Prometeus therapeutic proton complex at a dose of 0–12 Gy, and with the RUT‑15 therapeutic X‑ray unit at a dose of 0–12 Gy. The clonogenic test was used to analyze cell viability after irradiation. The appearance of the spheroids after irradiation was assessed by analyzing micromorphometry 24 hours after irradiation.
Results: A dose‑dependent reduction in the clonogenic activity of cells was demonstrated after irradiation with X‑rays and a proton beam at doses ranging from 1 to 12 Gy in the modified Bragg peak. It has been established that a dose of 6 Gy is optimal for analyzing the effectiveness of potential radiosensitizers using the clonogenic assay method for spheroids formed from B16/F10 cells.
Conclusion: The dose response of cell spheroids formed from tumor cells of the B16/F10 line to X‑ray irradiation and proton irradiation in a modified Bragg peak has been determined by analyzing their clonogenic activity and conducting micromorphometric analysis. The optimal radiation dose has been determined for rapid screening or for studying potential radiosensitizing substances.
Keywords: cellular spheroids, photon therapy, hadron therapy, melanoma, dose response
For citation: Mysina EA, Pivovarov NA, Bokl BA, Shemyakov AE, Popov AL. Influence of Different Type of Radiation on the Cell Survival from 3D Tumour Spheroids Formed from B16/F10 Melanoma Cells. Medical Radiology and Radiation Safety. 2026;71(6):19–24. DOI:10.33266/1024-6177-2026-71-6-19-24
References
1. Djavid A.R., Stonesifer C., Fullerton B.T., et al. Etiologies of Melanoma Development and Prevention Measures: a Review of the Current Evidence. Cancers (Basel). 2021;13;19:4914. Doi: 10.3390/cancers13194914.
2. Domingues B., Lopes J.M., Soares P., Pópulo H. Melanoma Treatment in Review. Immunotargets Ther. 2018;7:35-49. Doi: 10.2147/ITT.S134842.
3. Arrangoiz R. Melanoma Review: Epidemiology, Risk Factors, Diagnosis and Staging. JCTR. 2016;4;1:1. Doi: 10.11648/j.jctr.20160401.11.
4. Zhou C., Louwman M., Wakkee M., et al. Primary Melanoma Characteristics of Metastatic Disease: a Nationwide Cancer Registry Study. Cancers. 2021;13;17:4431. Doi: 10.3390/cancers13174431.
5. Caldaria A., Giuffrida R., Di Meo N., et al. Diagnosis and Treatment of Melanoma Bone Metastasis: a Multidisciplinary Approach. Dermatologic Therapy. 2020;33:6. Doi: 10.1111/dth.14193.
6. Arnold M., Singh D., Laversanne M., et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158;5:495-503. Doi: 10.1001/jamadermatol.2022.0160.
7. Deboever N., Feldman H.A., Hofstetter W.L., et al. The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. Journal of Surgical Research. 2022;277:125-130. Doi: 10.1016/j.jss.2022.04.021.
8. Garbe C., Peris K., Hauschild A., et al. Diagnosis and Treatment of Melanoma. European Consensus-Based Interdisciplinary Guideline – Update 2016. European Journal of Cancer. 2016;63:201-217. Doi: 10.1016/j.ejca.2016.05.005.
9. Benkhaled S., Schiappacasse L., Awde A., Kinj R. Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases. Cancers. 2024;16;6:1093. Doi: 10.3390/cancers16061093.
10. Delaney G., Barton M., Jacob S. Estimation of an Optimal Radiotherapy Utilization Rate for Melanoma: a Review of the Evidence. Cancer. 2004;100;6:1293-1301. Doi: 10.1002/cncr.20092.
11. Strojan P. Role of Radiotherapy in Melanoma Management. Radiol Oncol. 2010;44;1:1-12. Doi: 10.2478/v10019-010-0008-x.
12. Chan A.W., Lin H., Yacoub I., Chhabra A.M., Choi J.I., Simone C.B. Proton Therapy in Uveal Melanoma. Cancers (Basel). 2024;16;20:3497. Doi: 10.3390/cancers16203497.
13. Lin A., Swisher-McClure S., Millar L.B., Kirk M., Yeager C., Kassaee A. Proton Therapy for Head and Neck Cancer: Current Applications and Future Directions. Transl Cancer Res. 2012;1: 255-263. Doi: 10.3978/j.issn.2218-676X.2012.12.01.
14. Gollrad J., Böker A., Vitzthum S., et al. Proton Therapy for 166 Patients with Iris Melanoma. Ophthalmology Retina. 2023;7;3:266-274. Doi: 10.1016/j.oret.2022.08.026.
15. Verma V., Mehta M.P. Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. Clinical Oncology. 2016;28;8:e17-e27. Doi: 10.1016/j.clon.2016.01.034.
16. Thariat J., Salleron J., Maschi C., et al. Oncologic and Visual Outcomes after Postoperative Proton Therapy of Localized Conjunctival Melanomas. Radiat Oncol. 2019;14;1:239. Doi: 10.1186/s13014-019-1426-6.
17. Zenda S., Kawashima M., Nishio T., et al. Proton Beam Therapy as a Nonsurgical Approach to Mucosal Melanoma of the Head and Neck: a Pilot Study. International Journal of Radiation Oncology*Biology*Physics. 2011;81;1:135-139. Doi: 10.1016/j.ijrobp.2010.04.071.
18. McKay M.J., Kefford R.F. The Spectrum of in Vitro Radiosensitivity in Four Human Melanoma Cell Lines in not Accounted for by Differential Induction or Rejoining of DNA Double Strand Breaks. International Journal of Radiation Oncology*Biology*Physics. 1995;31;2:345-352. Doi: 10.1016/0360-3016(94)E0147-C.
19. Rofstad E.K., Mathiesen B., Galappathi K. Increased Metastatic Dissemination in Human Melanoma Xenografts after Subcurative Radiation Treatment. Cancer Research. 2004;64;1:13-18. Doi: 10.1158/0008-5472.CAN-03-2658.
20. Hirai T., Saito S., Fujimori H., et al. Radiosensitization by PARP Inhibition to Proton Beam Irradiation in Cancer Cells. Biochemical and Biophysical Research Communications. 2016;478;1:234-240. Doi: 10.1016/j.bbrc.2016.07.062.
21. Wang L., Cao J., Wang X., et al. Proton and Photon Radiosensitization Effects of Niraparib, a PARP‐1/‐2 Inhibitor, on Human Head and Neck Cancer Cells. Head & Neck. 2020;42;9:2244-2256. Doi: 10.1002/hed.26155.
22. Luo X., Gao S., Sun K., Dong Z., Yang S. PARP Inhibitors as Radiosensitizers: a Comprehensive Review of Preclinical Evidence and Clinical Applications. Front Oncol. 2025;15:1702121. Doi: 10.3389/fonc.2025.1702121.
23. Department of Gynecology and Obstetrics, University Hospital Ostrava, Czech Republic, Romanová M, Klát J. Adverse Events of PARP Inhibitors. Ceska Gynekol. 2021;86;1:54-60. Doi: 10.48095/cccg202154.
24. Babu B., Stoltz S.A., Mittal A., et al. Inorganic Nanoparticles as Radiosensitizers for Cancer Treatment. Nanomaterials. 2023;13;21:2873. Doi: 10.3390/nano13212873.
25. Matsumoto Y., Fukumitsu N., Ishikawa H., Nakai K., Sakurai H. A Critical Review of Radiation Therapy: from Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. JPM. 2021;11;8:825. Doi: 10.3390/jpm11080825.
26. Ma J., Shen H., Mi Z. Enhancing Proton Therapy Efficacy through Nanoparticle-Mediated Radiosensitization. Cells. 2024;13;22:1841. Doi: 10.3390/cells13221841.
27. Bonvalot S., Rutkowski P.L., Thariat J., et al. NBTXR3, a First-in-Class Radioenhancer Hafnium Oxide Nanoparticle, Plus Radiotherapy Versus Radiotherapy Alone in Patients with Locally Advanced Soft-Tissue Sarcoma (Act.In.Sarc): a Multicentre, Phase 2–3, Randomised, Controlled Trial. The Lancet Oncology. 2019;20;8:1148-1159. Doi: 10.1016/S1470-2045(19)30326-2.
28. Wagner M., Koyasu S. A 3D Skin Melanoma Spheroid-Based Model to Assess Tumor-Immune Cell Interactions. Bio-Protocol. 2020;10;23. Doi: 10.21769/BioProtoc.3839.
29. Saleh N.A., Rode M.P., Sierra J.A., et al. Three-Dimensional Multicellular Cell Culture for Anti-Melanoma Drug Screening: Focus on Tumor Microenvironment. Cytotechnology. 2021;73;1:35-48. Doi: 10.1007/s10616-020-00440-5.
30. Cordeiro S., Oliveira B.B., Valente R., et al. Breaking the Mold: 3D Cell Cultures Reshaping the Future of Cancer Research. Front Cell Dev Biol. 2024;12:1507388. Doi: 10.3389/fcell.2024.1507388.
31. Kapałczyńska M., Kolenda T., Przybyła W., et al. 2D and 3D Cell Cultures – a Comparison of Different Types of Cancer Cell Cultures. Aoms. 2018 Jun;14;4:910-919. Doi: 10.5114/aoms.2016.63743.
32. Sogomonyan A.S., Shipunova V.O., Soloviev V.D., Larionov V.I., Kotelnikova P.A., Deyev S.M. 3D Models of Cellular Spheroids as a Universal Tool for Studying the Cytotoxic Properties of Anticancer Compounds in Vitro. Acta Naturae. 2022;14;1:92-100. Doi: 10.32607/actanaturae.11603.
33. Raitanen J., Barta B., Hacker M., Georg D., Balber T., Mitterhauser M. Comparison of Radiation Response between 2D and 3D Cell Culture Models of Different Human Cancer Cell Lines. Cells. 2023;12;3:360. Doi: 10.3390/cells12030360.
34. Мысина Е.А., Колманович Д.Д. и др. Трехмерный клеточный сфероид как релевантная экспериментальная модель для скрининга потенциальных нанорадиосенсибилизаторов // Медицинская радиология и радиационная безопасность. 2025. Т.70. №5. С. 11–17 [Mysina Ye.A., Kolmanovich D.D., et al. Three-Dimensional Cellular Spheroid as a Relevant Experimental Model for Screening Potential Nanoradiosensitizers. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2025;70;5:11–17 (In Russ.)]. Doi: 10.33266/1024-6177-2025-70-5-11-17.
35. Мысина Е.А., Попова Н.Р. и др. Исследование влияния пучка протонов на динамику роста и жизнеспособность трехмерных клеточных сфероидов, сформированных из клеток карциномы 4T1 // Медицинская радиология и радиационная безопасность. 2025. Т.70. №4. С. 16–20 [Mysina Ye.A., Popova N.R., et al. Study of the Effect of a Proton Beam on the Growth Dynamics and Viability of Three-Dimensional Cellular Spheroids Formed from 4T1 Carcinoma Cells. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2025;70;4:16–20 (In Russ.)]. Doi: 10.33266/1024-6177-2025-70-4-16-20.
36. Sant S., Johnston P.A. The Production of 3D Tumor Spheroids for Cancer Drug Discovery. Drug Discovery Today: Technologies. 2017;23:27-36. Doi: 10.1016/j.ddtec.2017.03.002.
37. Brüningk S.C., Rivens I., Box C., Oelfke U., Ter Haar G. 3D Tumour Spheroids for the Prediction of the Effects of Radiation and Hyperthermia Treatments. Sci Rep. 2020;10;1:1653. Doi: 10.1038/s41598-020-58569-4.
38. Kumar M., Nassour-Caswell L.C., Alrefai H., et al. A High-Throughput Neurosphere-Based Colony Formation Assay to Test Drug and Radiation Sensitivity of Different Patient-Derived Glioblastoma Lines. Cells. 2024;13;23:1995. Doi: 10.3390/cells13231995.
PDF (RUS) Full-text article (in Russian)
Conflict of interest.The authors declare no conflict of interest.
Financing. The article was prepared within the framework of the RSCF grant No. 22-73-10231-P, https://rscf.ru/project/22-73-10231-P/.
Contribution. E.A.Mysina – work with spheroids (cultivation, irradiation, viability analysis), A.L. Popov – scientific text editing, A.E. Shemyakov – dosimetry at the proton therapeutic complex “Prometheus”, N.A. Pivovarov – irradiation of spheroids and dosimetry at the Prometheus CBT, B.A. Bokle – irradiation of spheroids at X-ray therapeutic unit RUT–15, A.L. Popov ‒ research design development, scientific guidance, manuscript writing.
Article received: 20.06.2026. Accepted for publication: 25.07.2026.




